E3 PreliminaryPreliminaryPEM unclearCase-ControlPeer-reviewedMachine draft
A multidisciplinary approach to study a couple of monozygotic twins discordant for the chronic fatigue syndrome: a focus on potential salivary biomarkers.
Ciregia, Federica, Giusti, Laura, Da Valle, Ylenia et al. · Journal of translational medicine · 2013 · DOI
Quick Summary
Researchers studied saliva samples from identical twins—one with ME/CFS and one healthy—to look for protein differences that might help diagnose the disease. They found 13 proteins that were expressed differently in the sick twin compared to the healthy twin, with many of these proteins linked to inflammation and immune system function. This suggests that a simple saliva test might one day help doctors diagnose ME/CFS more reliably.
Why It Matters
This study provides preliminary evidence that ME/CFS involves measurable protein abnormalities in saliva, offering hope for developing a non-invasive diagnostic biomarker. The focus on inflammatory and immune pathways may help clarify the biological mechanisms underlying ME/CFS, potentially directing future therapeutic research.
Observed Findings
- 13 proteins showed differential expression in the CFS twin versus the healthy twin
- 9 proteins were upregulated and 4 were downregulated in the CFS patient
- Differentially expressed proteins mapped to functional categories including inflammatory response, immune system, and metabolism
- 5 candidate proteins (14-3-3 protein zeta/delta, cyclophilin A, Cystatin-C, Protein S100-A7, zinc-alpha-2-glycoprotein) were validated by western blot
- Pathway analysis highlighted inflammatory response networks as potentially central to CFS pathogenesis
Inferred Conclusions
- Salivary proteomic profiling can detect protein abnormalities in ME/CFS that may distinguish affected individuals from healthy controls
- Inflammatory response pathways appear to be implicated in CFS pathophysiology based on the protein networks identified
- A panel of salivary biomarkers could potentially be developed for diagnostic and pathophysiological research purposes in ME/CFS
Remaining Questions
- Do these protein differences replicate in a larger, independent cohort of CFS patients and matched healthy controls?
- Are the identified proteins present across clinically diverse ME/CFS presentations, or do they vary by patient subtype or disease phase?
What This Study Does Not Prove
This study does not prove that any of these proteins cause ME/CFS or that they are unique diagnostic markers—findings from a single twin pair cannot be generalized to the broader ME/CFS population. The differential expression could reflect individual variation rather than disease-specific pathology, and correlation between protein levels and disease does not establish causation.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Metadata
- DOI
- 10.1186/1479-5876-11-243
- PMID
- 24088505
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →